X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Launch of The First Pipeline Assessment By Vaccines Europe

Content Team by Content Team
5th December 2022
in Drug Development, News

With 100 vaccine candidates as of July 2022, Vaccines Europe has released its first pipeline evaluation of the 15 firms that make up its membership.

The analysis uncovered a pipeline that uses a variety of new technology platforms to address present and upcoming problems like antimicrobial resistance (AMR) and respiratory tract infections. According to the data, 46% of the vaccine ideas are directed at illnesses for which there isn’t a vaccine yet. A fundamental shift to a life-course strategy for vaccination is also required, as 80% of the vaccine candidates are directed at the adult population. According to the paper, the COVID-19 vaccinations serve as a powerful reminder that planning is essential.

Four steps from the pipeline review to safeguard adults from diseases that can be prevented by vaccination

  • Assure ongoing financing and include adult immunisation in national immunisation programmes.
  • Raise the level of knowledge about the advantages of adult immunisation among the general public and medical professionals.
  • Improve adult immunisation convenience and access.
  • Create online vaccination records to increase immunisation rates.

According to Vaccinations Europe, despite the availability of new vaccines over the past five years, European Union (EU) Member States have only made modest investments in their immunisation programmes.

Currently, a thorough routine immunisation programme can avert about 20 malignancies and linked infectious diseases that are both life-threatening and debilitating at every stage of life. Inequitable access to vaccines across the EU, low uptake, and vaccine hesitancy, particularly for adolescent and adult immunizations, were shown to be the results of 77% of the States spending less than 0.5% of their healthcare expenditure on immunisation.

According to the evaluation of the vaccination pipeline, access to the vaccine market varies across Europe. A third of states have vaccine access wait times longer than six years, and most states’ vaccine procurement processes don’t promote fair competition, prompt vaccine access, or long-term supply.

The analysis found that whereas children’s vaccination schedules are well-established throughout Europe, adult immunisation programmes are not. As a result, country preparedness to prioritise and effectively implement adult immunisation programmes must be tackled as a matter of paramount concern. According to Vaccines Europe, in order to achieve the goals of the Immunization Agenda 2030 and the European Beating Cancer Plan, certain activities must be undertaken. The organisation contends that when establishing Europe’s research ecosystem via amendment of the General Pharmaceutical Legislation, it is essential to take vaccine specificities into account.

Additional measures To make Europe appealing to the vaccine industry and guarantee that there is fairness in vaccination access to create resilient communities and healthcare systems, Vaccines Europe asks for early, open, and ongoing communication, collaboration, and collaboration among all stakeholders.

Previous Post

Non-Vaccine mRNA Therapeutics To Earn $2 Billion By 2028

Next Post

EMA Urges The Withdrawal of Pholcodine Drugs From EU Market

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post
Arena Financial results

EMA Urges The Withdrawal of Pholcodine Drugs From EU Market

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In